<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263652</url>
  </required_header>
  <id_info>
    <org_study_id>SpinePainIMPO</org_study_id>
    <nct_id>NCT01263652</nct_id>
  </id_info>
  <brief_title>Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients</brief_title>
  <official_title>The Relationship Between Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Galilee Hospital-Nahariya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Galilee Hospital-Nahariya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a randomized double blind study, to determine whether patient
      analgesic delivery mode preference affects pain reduction quality in non-surgical spine
      patients.

      The patients will receive both intra-muscular and oral non-narcotic analgesics and placebo.
      During the study period, pain reduction parameters will be collected. At the end of the study
      period, the investigators will attempt to find a correlation between pre-study patient
      preferences and the quality of the pain reduction achieved.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    inability to complete recruitment as planned
  </why_stopped>
  <start_date type="Anticipated">December 31, 2010</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain scores on visual analog scale</measure>
    <time_frame>visual analog scale will be mesuered before and one hour following every pain medication delivery</time_frame>
    <description>up to 7 days for each patient per hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Questionnaire assessing pain and pain relief</measure>
    <time_frame>Before administaration of pain control medication and one hour following analgesic administration</time_frame>
    <description>A questionnaire will be filled immediately before and one hour following analgesic administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient preference Questionnaire</measure>
    <time_frame>before first analgesic administration at the current hositalization</time_frame>
    <description>every patient will be asked for his prefered analgesic delivery method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain Relief</condition>
  <arm_group>
    <arm_group_label>IMmed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving intra-muscular medication and oral placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POmed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving intra-muscular placebo and oral medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac hydroxyethylpyrrolidine</intervention_name>
    <description>IM/PO</description>
    <arm_group_label>IMmed</arm_group_label>
    <arm_group_label>POmed</arm_group_label>
    <other_name>Voltaren, Abitren</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orphenadrine</intervention_name>
    <description>IM/PO orphenadrine</description>
    <arm_group_label>IMmed</arm_group_label>
    <arm_group_label>POmed</arm_group_label>
    <other_name>Flexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>IM/PO tramadol</description>
    <arm_group_label>IMmed</arm_group_label>
    <arm_group_label>POmed</arm_group_label>
    <other_name>Tramadex, Tramal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyrone</intervention_name>
    <description>PO/IM Dipyrone</description>
    <arm_group_label>IMmed</arm_group_label>
    <arm_group_label>POmed</arm_group_label>
    <other_name>Optalgin, Phanalgin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic and acute back pain

        Exclusion Criteria:

          -  Recent Spine Surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nimrod Rahamimov, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Galilee Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Galilee Hospital-Nahariya</investigator_affiliation>
    <investigator_full_name>Nimrod Rahamimov</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>intramuscular</keyword>
  <keyword>oral</keyword>
  <keyword>spine</keyword>
  <keyword>preference</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Diclofenac hydroxyethylpyrrolidine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Orphenadrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

